Silence Therapeutics Q3 Net Loss Narrows

MT Newswires Live11-12

Silence Therapeutics (SLN) reported Thursday its Q3 net loss narrowed to $0.08 per diluted share, compared with a loss of $0.15 a year earlier.

Analysts polled by FactSet expected a loss of $0.08.

The company ended the quarter with $247.7 million in cash and cash equivalents, including $201.3 million in gross proceeds from a public offering in August.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment